LXRX News and Press, Lexicon Pharmaceuticals Inc. From 10/13/23

2023-10-13 08:12:01 ET EHang Holdings  ( EH ) +47% Successfully Obtains Type Certificate for EH216-S Passenger-Carrying UAV System Issued by Civil Aviation Administration of China. Comtech Telecommunications ( CMTL ) +15% . SEALSQ  ( LAES ) +13% ....

Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment of heart failure Abstracts published in the Journal of Managed Care & Specialty Pharmacy (JMCP) THE WOODLANDS, ...

2023-10-10 11:25:34 ET Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) were up more than 15% as of 11 a.m. on Tuesday after Express Scripts said it will give certain clients access to Lexicon's drug Inpefa. The healthcare stock is still down more than 39% so far this year. ...

2023-10-10 10:00:01 ET More on Health Care Select Sector SPDR Citi turns cautious on pharmaceuticals and biotech BofA Securities: Which small cap non-earner stocks to avoid Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further deta...

2023-10-09 17:20:56 ET More on Lexicon Pharmaceuticals Looking Back In On Lexicon Pharmaceuticals Lexicon Pharmaceuticals Underway With Inpefa, But A Lot Of Hard Work Lexicon Rolls Out Inpefa For Heart Failure Amid Robust Competition Seeking Alpha’s Qu...

INPEFA recently approved by FDA for treatment of heart failure Express Scripts has determined that it will list INPEFA as a preferred product on Medicare national formularies on November 1, 2023 THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceutic...

THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023. Mr. Garner has over 25 years of pharmaceutica...

2023-10-02 02:34:38 ET Summary Lexicon Pharmaceuticals' primary drug candidate, INPEFA (sotagliflozin), has received FDA approval for the treatment of heart failure. INPEFA has a broad label and can be used for heart failure patients with or without diabetes, competing with establ...

INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of two randomized, double-blind, placebo-controlled Phase 3 cardiovascular outcomes studies that led to FDA approval THE WOODLANDS, Texas, Sept. 28, 2023 (G...

INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain THE WOODLANDS, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceut...